Amedisys (NASDAQ:AMED) had its price objective lifted by Royal Bank of Canada to $150.00 in a report issued on Friday morning, The Fly reports. The firm currently has an outperform rating on the health services provider’s stock.
Other analysts have also recently issued research reports about the company. ValuEngine upgraded Amedisys from a hold rating to a buy rating in a research report on Saturday, June 22nd. BidaskClub upgraded Amedisys from a buy rating to a strong-buy rating in a research report on Friday, July 26th. Oppenheimer increased their target price on Amedisys from $140.00 to $150.00 in a research report on Thursday, August 1st. Raymond James increased their target price on Amedisys from $140.00 to $144.00 and gave the stock an outperform rating in a research report on Monday, July 15th. Finally, Jefferies Financial Group set a $150.00 target price on Amedisys and gave the stock a buy rating in a research report on Monday, July 8th. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Buy and an average target price of $135.90.
Shares of AMED opened at $130.83 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.91 and a current ratio of 0.88. The stock has a 50-day moving average of $125.88. The stock has a market capitalization of $4.33 billion, a PE ratio of 36.04, a price-to-earnings-growth ratio of 1.67 and a beta of 1.41. Amedisys has a 52 week low of $97.38 and a 52 week high of $141.98.
In related news, insider Michael Paul North sold 10,067 shares of the stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $130.00, for a total transaction of $1,308,710.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bruce D. Perkins purchased 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were purchased at an average cost of $111.84 per share, with a total value of $279,600.00. Following the completion of the purchase, the director now owns 22,088 shares of the company’s stock, valued at approximately $2,470,321.92. The disclosure for this purchase can be found here. Insiders have sold 51,278 shares of company stock valued at $6,082,207 in the last quarter. 2.90% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in AMED. Riverbridge Partners LLC bought a new position in Amedisys during the second quarter valued at approximately $80,465,000. Norges Bank bought a new position in Amedisys during the fourth quarter valued at approximately $68,342,000. Eagle Asset Management Inc. bought a new position in Amedisys during the second quarter valued at approximately $35,359,000. Marshall Wace LLP boosted its stake in Amedisys by 289.2% during the first quarter. Marshall Wace LLP now owns 220,503 shares of the health services provider’s stock valued at $27,180,000 after buying an additional 163,842 shares during the last quarter. Finally, AJO LP boosted its stake in Amedisys by 3,004.4% during the first quarter. AJO LP now owns 109,988 shares of the health services provider’s stock valued at $13,557,000 after buying an additional 106,445 shares during the last quarter. 87.98% of the stock is owned by institutional investors.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
See Also: What is a Call Option?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.